Compugen Ltd. (CGEN) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
3.22
↑+83% vs avg
5yr avg: 1.76
30Y Low1.8·High1.8
P/FCF
↑
6.07
↑+65% vs avg
5yr avg: 3.67
30Y Low2.8·High4.6
P/B Ratio
↓
1.84
↓-14% vs avg
5yr avg: 2.15
30Y Low0.7·High10.9
ROE
↑
44.8%
↓+413% vs avg
5yr avg: -14.3%
30Y Low-92%·High45%
Debt/EBITDA
0.09
+0% vs avg
5yr avg: 0.09
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Compugen Ltd. trades at 5.3x earnings, 31% above its 5-year average of 4.0x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 76%. On a free-cash-flow basis, the stock trades at 6.1x P/FCF, 65% above the 5-year average of 3.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $190M | $144M | $137M | $174M | $62M | $362M | $964M | $379M | $120M | $128M | $259M |
| Enterprise Value | $102M | $56M | $122M | $161M | $53M | $357M | $960M | $373M | $74M | $98M | $198M |
| P/E Ratio → | 5.29 | 4.03 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.61 | 1.97 | 4.92 | 5.19 | 8.26 | 60.35 | 481.92 | — | 6.74 | — | 364.28 |
| P/B Ratio | 1.84 | 1.40 | 2.49 | 2.65 | 0.80 | 3.39 | 8.05 | 9.90 | 3.22 | 4.37 | 4.08 |
| P/FCF | 6.07 | 4.58 | 2.77 | — | — | — | — | — | — | — | — |
| P/OCF | 6.01 | 4.54 | 2.76 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Compugen Ltd.'s enterprise value stands at 3.2x EBITDA, 83% above its 5-year average of 1.8x. The Healthcare sector median is 14.2x, placing the stock at a 77% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.77 | 4.37 | 4.81 | 7.04 | 59.50 | 479.94 | — | 4.17 | — | 277.86 |
| EV / EBITDA | 3.22 | 1.76 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 3.27 | 1.78 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 1.78 | 2.46 | — | — | — | — | — | — | — | — |
CGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Compugen Ltd. earns an operating margin of 43.1%. Operating margins have expanded from -38.8% to 43.1% over the past 3 years, signaling improving operational efficiency. Return on equity of 44.8% is exceptionally high. ROIC of 85.9% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | 87.3% | 71.5% | 94.0% | 87.0% | 88.7% | 97.0% | — | 94.2% | — | 68.7% |
| Operating Margin | 43.1% | 43.1% | -53.4% | -38.8% | -471.7% | -584.6% | -1574.8% | — | -130.5% | — | -4576.3% |
| Net Profit Margin | 48.6% | 48.6% | -51.1% | -56.1% | -449.3% | -570.0% | -1484.9% | — | -127.0% | — | -4425.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 44.8% | 44.8% | -23.6% | -26.2% | -36.5% | -30.2% | -37.6% | -72.4% | -67.9% | -79.9% | -41.1% |
| ROA | 26.0% | 26.0% | -12.0% | -17.4% | -29.8% | -25.3% | -30.9% | -51.1% | -49.2% | -67.5% | -37.0% |
| ROIC | 85.9% | 85.9% | -24.1% | -16.0% | -31.2% | -24.2% | -32.0% | -183.3% | — | -6593.1% | -466.9% |
| ROCE | 27.3% | 27.3% | -15.7% | -14.7% | -35.9% | -28.9% | -36.0% | -64.1% | -61.3% | -75.6% | -41.0% |
CGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Compugen Ltd. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (97% below the sector average of 3.2x). The company holds a net cash position — cash of $91M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.05 | 0.02 | 0.02 | 0.03 | 0.03 | 0.09 | — | — | — |
| Debt / EBITDA | 0.09 | 0.09 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.85 | -0.28 | -0.19 | -0.12 | -0.05 | -0.03 | -0.16 | -1.23 | -1.04 | -0.97 |
| Net Debt / EBITDA | -2.76 | -2.76 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.80 | -0.31 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -437.97 | -419.10 | -1244.78 | -1402.96 | -706.10 | -875.84 | -37.46 | -72.94 | -46.22 |
Net cash position: cash ($91M) exceeds total debt ($3M)
CGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Compugen Ltd.'s current ratio of 6.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.36x to 6.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.56 | 6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.66 | 5.03 | 13.22 |
| Quick Ratio | 6.56 | 6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.80 | 5.31 | 13.66 |
| Cash Ratio | 6.45 | 6.45 | 5.12 | 1.93 | 6.99 | 6.85 | 11.76 | 6.43 | 4.57 | 4.91 | 12.98 |
| Asset Turnover | — | 0.46 | 0.24 | 0.28 | 0.08 | 0.05 | 0.01 | — | 0.33 | — | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1.47 | 3.52 | 668.91 | 15.43 | 11.44 | 365.00 | — | 3.42 | — | 42.04 |
CGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Compugen Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 18.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 18.9% | 24.8% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 16.5% | 21.8% | 36.1% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $94M | $90M | $88M | $87M | $84M | $80M | $64M | $55M | $51M | $51M |
Peer Comparison
Compare CGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CGENYou | $190M | 5.3 | 3.2 | 6.1 | 87.3% | 43.1% | 44.8% | 85.9% | 0.1 |
 RXRX | $1B | -2.2 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 SDGR | $1B | -11.2 | — | 94.5 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 ABSI | $1B | -8.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTX | $205M | -2.0 | — | — | — | — | -28.9% | -22.5% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CGEN — Frequently Asked Questions
Quick answers to the most common questions about buying CGEN stock.
What is Compugen Ltd.'s P/E ratio?
Compugen Ltd.'s current P/E ratio is 5.3x. The historical average is 4.0x. This places it at the 100th percentile of its historical range.
What is Compugen Ltd.'s EV/EBITDA?
Compugen Ltd.'s current EV/EBITDA is 3.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 1.8x.
What is Compugen Ltd.'s ROE?
Compugen Ltd.'s return on equity (ROE) is 44.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -37.9%.
Is CGEN stock overvalued?
Based on historical data, Compugen Ltd. is trading at a P/E of 5.3x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Compugen Ltd.'s profit margins?
Compugen Ltd. has 87.3% gross margin and 43.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Compugen Ltd. have?
Compugen Ltd.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.